Invivyd (NASDAQ:IVVD) Insider Jill Andersen Sells 37,256 Shares of Stock

Invivyd, Inc. (NASDAQ:IVVD) insider Jill Andersen sold 37,256 shares of Invivyd stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $0.72, for a total value of $26,824.32. Following the completion of the transaction, the insider directly owned 314,480 shares of the company’s stock, valued at approximately $226,425.60. This represents a 10.59% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jill Andersen also recently made the following trade(s):

• On Tuesday, August 18th, Jill Andersen sold 30,706 shares of Invivyd stock. The shares were sold at an average price of $0.84, for a total transaction of $25,793.04.

Invivyd Trading Up 17.2%

IVVD stock opened at $0.87 on Wednesday. The stock has a market capitalization of $255.75 million, a PE ratio of -2.63 and a beta of 0.71. Invivyd, Inc. has a 12-month low of $0.48 and a 12-month high of $3.07. The stock’s 50 day simple moving average is $0.77 and its 200 day simple moving average is $1.23.

Invivyd (NASDAQ:IVVD) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.03). The business had revenue of $14.29 million for the quarter, compared to analysts’ expectations of $14.40 million. Invivyd had a negative net margin of 183.90% and a negative return on equity of 59.73%. On average, research analysts predict that Invivyd, Inc. will post -0.52 earnings per share for the current year.

Analyst Upgrades and Downgrades

IVVD has been the topic of a number of research reports. HC Wainwright reissued a “buy” rating on shares of Invivyd in a report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Invivyd in a research report on Friday, July 24th. Wall Street Zen cut shares of Invivyd from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 16th. Finally, BTIG Research reaffirmed a “buy” rating on shares of Invivyd in a report on Tuesday, July 7th. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $8.00.

Key Invivyd News

Here are the key news stories impacting Invivyd this week:

• Neutral Sentiment: Robert D. Allen III, Jill Andersen, CFO William E. Duke, Julie Green, and Timothy Edward Lee each sold shares at prices of approximately $0.72 or $0.84. The sales reduced each insider’s direct holdings by roughly 9% to 11%. SEC insider transaction filing
• Neutral Sentiment: The filings state that the transactions were made to cover tax-withholding obligations tied to the vesting of equity awards. Because the sales were not described as discretionary reductions or based on a negative outlook, they are less concerning than open-market sales intended to exit positions. SEC insider transaction filing
• Negative Sentiment: The concentration of sales by multiple insiders may nevertheless create a modest overhang for Invivyd stock, particularly given the company’s small market capitalization and recent elevated trading volume. However, the disclosed tax-related purpose limits the bearish signal.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. OMERS ADMINISTRATION Corp grew its stake in Invivyd by 9.0% in the first quarter. OMERS ADMINISTRATION Corp now owns 106,900 shares of the company’s stock worth $139,000 after purchasing an additional 8,800 shares in the last quarter. Bank of New York Mellon Corp lifted its position in Invivyd by 54.3% during the first quarter. Bank of New York Mellon Corp now owns 27,184 shares of the company’s stock valued at $35,000 after acquiring an additional 9,568 shares during the last quarter. Courier Capital LLC acquired a new stake in shares of Invivyd in the 4th quarter worth $25,000. Bronte Capital Management Pty Ltd. acquired a new stake in Invivyd in the fourth quarter worth about $27,000. Finally, DRW Securities LLC purchased a new stake in Invivyd during the 4th quarter worth approximately $27,000. 70.36% of the stock is currently owned by institutional investors.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.